

In re: MacDonald et al.  
Serial No.: 09/288,837  
Filed: April 8, 1999  
Page 2 of 18

**Listing of Claims.**

Please amend the claims as shown below by deleting the material indicated by strike-through and adding the underlined material. This listing of claims will replace all prior versions and listings of the claims in this application.

**Claims 1-83 (Cancelled)**

84. (Currently amended) A composition comprising infectious alphavirus replicon particles in an immunogenically effective amount to prevent or treat cancer, wherein said alphavirus replicon particles comprise one or more heterologous nucleotide sequences encoding a naturally occurring cancer cell antigen; and wherein said alphavirus replicon particles infect antigen-presenting cells, and further wherein said alphavirus replicon particles comprise one or more attenuating mutations.

**Claims 85-88. (Cancelled)**

89. (Original) The composition of Claim 84, wherein each of said one or more heterologous nucleotide sequences is operably associated with a promoter.

90. (Original) The composition of Claim 89, wherein said promoter operably associated with each of said one or more heterologous nucleotide sequences is an alphavirus 26S subgenomic promoter.

91. (Currently amended) The composition of Claim 84, wherein said naturally occurring cancer cell antigen is selected from the group consisting of a helper T cell epitope, a cytotoxic T cell epitope, a T-dependent B cell epitope, and a T-independent B cell epitope.

In re: MacDonald et al.  
Serial No.: 09/288,837  
Filed: April 8, 1999  
Page 3 of 18

92. (Currently amended) The composition of Claim 84, wherein said naturally occurring cancer cell antigen is a cell-surface protein or peptide.

93. (Original) A pharmaceutical formulation comprising the composition of Claim 84 in a pharmaceutically acceptable carrier.

94. (Cancelled)

95. (Currently amended) A composition comprising infectious Venezuelan Equine Encephalitis (VEE) replicon particles in an immunogenically effective amount to prevent or treat cancer, wherein said VEE replicon particles comprise one or more heterologous nucleotide sequences encoding a naturally occurring cancer cell antigen; and wherein said VEE replicon particles infect antigen-presenting cells, and further wherein said VEE replicon particles comprise one or more attenuating mutations.

96. (Cancelled)

97. (Original) The composition of Claim 95, wherein at least one of said one or more attenuating mutations is selected from the group consisting of codons at E2 amino acid position 76 which specify an attenuating amino acid, codons at E2 amino acid position 120 which specify an attenuating amino acid, codons at E2 amino acid position 209 which specify an attenuating amino acid, codons at E1 amino acid 272 which specify an attenuating mutation, codons at E1 amino acid 81 which specify an attenuating mutation, and codons at E1 amino acid 253 which specify an attenuating mutation, and the deletion of E3 amino acids 56-59.

98. (Original) The composition of Claim 95, wherein each of said one or more heterologous nucleotide sequences is operably associated with a promoter.

In re: MacDonald et al.  
Serial No.: 09/288,837  
Filed: April 8, 1999  
Page 4 of 18

99. (Original) The composition of Claim 98, wherein said promoter operably associated with each of said one or more heterologous nucleotide sequences is an alphavirus 26S subgenomic promoter.

100. (Currently amended) The composition of Claim 95, wherein said naturally occurring cancer cell antigen is selected from the group consisting of a helper T cell epitope, a cytotoxic T cell epitope, a T-dependent B cell epitope, and a T-independent B cell epitope.

101. (Currently amended) The composition of Claim 95, wherein said naturally occurring cancer cell antigen is a cell-surface protein or peptide.

102. (Original) A pharmaceutical formulation comprising the composition of Claim 95 in a pharmaceutically acceptable carrier.

103. (Currently amended) A composition comprising infectious alphavirus replicon particles in an amount effective to provide a protective immune response, wherein said alphavirus replicon particles comprise one or more heterologous nucleotide sequences encoding a Her2 gene product, and wherein said alphavirus replicon particles infect antigen-presenting cells, and further wherein said alphavirus replicon particles comprise one or more attenuating mutations.

104. (Currently amended) A composition comprising infectious Venezuelan Equine Encephalitis (VEE) replicon particles in an amount effective to provide a protective immune response, wherein said VEE replicon particles comprise one or more heterologous nucleotide sequences encoding a Her2 gene product, and wherein said ~~alphavirus~~ VEE replicon particles infect antigen-presenting cells, and further wherein said VEE replicon particles comprise one or more attenuating mutations.

In re: MacDonald et al.  
Serial No.: 09/288,837  
Filed: April 8, 1999  
Page 5 of 18

Claims 105-108 (Cancelled).

109. (Currently amended) The composition of Claim 84 ~~105~~, wherein said antigen-presenting cells are dendritic cells.

Claims 110-113. (Cancelled)

114. (Currently amended) The composition of Claim 95 ~~110~~, wherein said antigen-presenting cells are dendritic cells.